Figure 3 - uploaded by Sanjeev Kumar Shangary
Content may be subject to copyright.
Timeline and Product History for Vimpat (A) An overview of Vimpat's history from USFDA approval to subsequent introduction of formulations and patient populations; (B) Increasing annual global sales (sales are shown in Euro).
Source publication
Drug Life Cycle Management (LCM) includes a variety of strategies that are implemented by biotech and pharmaceutical companies to uncover the hidden value of the drug, maximize their sales, and extend their commercial lives. Drug reformulation is one of the most widely used line extension strategies, which expands the therapeutic utility of drugs i...
Context in source publication
Context 1
... most common adverse events associated with the use of Vimpat are diplopia, nausea and headache. Lacosamide was initially launched in two formulations, as film-coated oral tablets with different strengths and as an intravenous injection for temporary use in cases where a requirement for acute administration exists, but oral administration was not feasible (Figure 3) [17,18]. The bioavailability and tolerability of the oral and intravenous formulations are comparable for Vimpat. ...
